Hims & Hers Health, Inc. (NYSE:HIMS) COO Sells $1,986,613.45 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 67,687 shares of Hims & Hers Health stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $29.35, for a total transaction of $1,986,613.45. Following the completion of the sale, the chief operating officer now owns 706,872 shares in the company, valued at approximately $20,746,693.20. This trade represents a 8.74 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Melissa Baird also recently made the following trade(s):

• On Tuesday, December 10th, Melissa Baird sold 85,561 shares of Hims & Hers Health stock. The shares were sold at an average price of $31.01, for a total transaction of $2,653,246.61.
• On Monday, November 18th, Melissa Baird sold 58,750 shares of Hims & Hers Health stock. The shares were sold at an average price of $21.04, for a total transaction of $1,236,100.00.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $30.89 on Friday. Hims & Hers Health, Inc. has a fifty-two week low of $8.51 and a fifty-two week high of $35.02. The business has a 50-day simple moving average of $28.22 and a two-hundred day simple moving average of $22.17. The firm has a market cap of $6.75 billion, a price-to-earnings ratio of 70.20 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the previous year, the firm earned ($0.04) EPS. Hims & Hers Health’s revenue was up 77.1% on a year-over-year basis. As a group, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on HIMS. Needham & Company LLC raised their price objective on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, January 6th. Morgan Stanley began coverage on Hims & Hers Health in a research report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price objective for the company. Deutsche Bank Aktiengesellschaft raised their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. TD Cowen reissued a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Finally, BTIG Research began coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus target price of $25.13.

Hedge Funds Weigh In On Hims & Hers Health

A number of hedge funds have recently bought and sold shares of the business. Raleigh Capital Management Inc. lifted its holdings in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the period. GAMMA Investing LLC increased its position in shares of Hims & Hers Health by 2,173.7% during the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after purchasing an additional 2,152 shares during the last quarter. Quest Partners LLC lifted its stake in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Hims & Hers Health by 115.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,560 shares of the company’s stock worth $110,000 after buying an additional 2,442 shares during the last quarter. Finally, Ausbil Investment Management Ltd purchased a new position in shares of Hims & Hers Health in the fourth quarter worth approximately $127,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.